News

May 7, 2019

Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the AAN Annual Meeting

Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the AAN Annual Meeting

Genentech, a member of the Roche Group, recently announced new data at the 71st American Academy of Neurology (AAN) Annual Meeting from the dose-finding Part 1 of the pivotal...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 6, 2019

AveXis Presents Data at AAN Annual Meeting Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients

AveXis Presents Data at AAN Annual Meeting Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients

AveXis, a Novartis company, recently announced interim data from ongoing trials of the investigational product...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 6, 2019

Biogen Presents Data Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® at AAN Annual Meeting

Biogen Presents Data Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® at AAN Annual Meeting

Biogen today announced new data affirming the safety and durability of SPINRAZA (nusinersen) and highlighting its clinically meaningful benefits for...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 2, 2019

Cure SMA and Genentech Partner to Provide Travel Support to Adults with SMA the Annual SMA Conference

Cure SMA and Genentech Partner to Provide Travel Support to Adults with SMA the Annual SMA Conference

Cure SMA is thrilled to announce that we will be extending travel scholarship opportunities to adults with SMA (18 and over) who are attending the 2019 Annual SMA Conference, taking place June 28-July 1, 2019 at Disneyland Resort in Anaheim, CA.

Thanks to a generous grant funded by...

READ MORE   |  

Topics: Support & Care, Conference, Front Page News

May 1, 2019

Biogen to Present Data at AAN Highlighting Spinraza and Emerging Biomarkers for SMA

Biogen to Present Data at AAN Highlighting Spinraza and Emerging Biomarkers for SMA

Biogen today announced it will present new data focusing on SMA at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.,...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 1, 2019

Novartis to Present Data Regarding Spinal Muscular Atrophy (SMA) and Zolgensma® at the American Academy of Neurology Meeting

Novartis announced today it will present data regarding spinal muscular atrophy (SMA) at the upcoming 71st American Academy of Neurology (AAN) meeting May 4 - 10 in...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

April 29, 2019

2019 Annual SMA Conference Registration Closes May 17

2019 Annual SMA Conference Registration Closes May 17

Registration for the 2019 Annual SMA Conference closes on Friday, May 17th.

Hotel rooms are rapidly booking up – be sure to make your reservations ASAP before they’re all sold out!

Please note when arranging your travel plans...

READ MORE   |  

Topics: Conference, Front Page News

April 29, 2019

Genentech Presents New Data at the 2019 AAN Annual Meeting

Genentech Presents New Data at the 2019 AAN Annual Meeting

Genentech, a member of the Roche Group, announced today that new data will be presented at the 71st American Academy of Neurology (AAN) Annual Meeting from May 4-10 in...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

April 24, 2019

Community Spotlight: Kyle and Laura Derkowski

Community Spotlight: Kyle and Laura Derkowski

Kyle and Laura Derkowski live in Ashburn, Virginia and are co-chairs of the Cure SMA Virginia Chapter. Kyle is originally from Schenectady, New York and Laura from Bethlehem, Pennsylvania; the pair met during their first year in college through a mutual friend and were married in December...

READ MORE   |  

Topics: Community & Awareness, Front Page News

April 17, 2019

AveXis Data Reinforces Effectiveness of Zolgensma® in Treating SMA Type 1

AveXis Data Reinforces Effectiveness of Zolgensma® in Treating SMA Type 1

AveXis, a Novartis company, today announced that interim data from its Phase 3 STR1VE trial of Zolgensma®(AVXS-101) in spinal muscular atrophy Type 1 showed prolonged event-free survival,...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 31 - 40 of 652  Previous12345678910Next

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software